SCHEMBL30745744

SCHEMBL30745744

Cc1ccnc(Nc2nc(-c3ccc(Cl)cn3)cs2)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 13/20 0.72
KMT2A Q03164 13/20 0.72
NPC1 O15118 10/20 0.72
RAB9A P51151 9/20 0.72
KCNN1 Q92952 2/20 0.68
KCNN2 Q9H2S1 2/20 0.68
KCNN3 Q9UGI6 2/20 0.68
SLC2A1 P11166 3/20 0.67
CASP3 P42574 2/20 0.61
SENP8 Q96LD8 2/20 0.61
SENP7 Q9BQF6 2/20 0.61
SENP6 Q9GZR1 2/20 0.61
POLB P06746 2/20 0.58
GAA P10253 1/20 0.58
NR2F2 P24468 1/20 0.58
MAPT P10636 5/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
MAPK1 P28482 2/20 0.54
SYK P43405 1/20 0.54
LMNA P02545 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27039690 1.00 MEN1 (0.72) MEN1KMT2ANPC1RAB9AKCNN1
SCHEMBL24357989 0.89 KCNN1 (0.73) MEN1KMT2ANPC1RAB9AKCNN1
SCHEMBL27040337 0.85 MEN1 (0.72) MEN1KMT2ANPC1RAB9AKCNN1
SCHEMBL30745786 0.83 KCNN1 (0.65) MEN1KMT2ANPC1RAB9AKCNN1
SCHEMBL24358162 0.83 KCNN1 (0.65) MEN1KMT2ANPC1RAB9AKCNN1
SCHEMBL24358043 0.83 KCNN1 (0.65) MEN1KMT2ANPC1RAB9AKCNN1
SCHEMBL24357955 0.83 KCNN1 (0.65) MEN1KMT2ANPC1RAB9AKCNN1
SCHEMBL5173768 0.83 KCNN1 (0.80) MEN1KMT2ANPC1RAB9AKCNN1
SCHEMBL29601174 0.83 KCNN1 (0.80) MEN1KMT2ANPC1RAB9AKCNN1
SCHEMBL24358169 0.82 MEN1 (0.74) MEN1KMT2ANPC1RAB9AKCNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025891-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025891-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CYP8B1, PAH, INHA MEN1 2606/4885KMT2A 1911/4885NPC1 2626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.